You searched for "metabolic"
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy
There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...Understanding Stauffer’s syndrome
Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...Immunotherapy in renal cancer
Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...A review of the diagnosis and management of urethral caruncles
Introduction The innocuous urethral caruncle is the most common benign urethral lesion in females. It can pose a significant challenge to urologists due to the plethora of differentials and poor evidence surrounding management. In 1926, Ferrier eloquently described the macroscopic...Recent developments in bladder cancer
There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...Benign upper tract abnormalities
Case 1 A 28-year-old lady has been referred to your clinic with right loin pain. She has no significant past medical history but mentions that she and her partner have been trying to get pregnant. She has an US renal...
Active surveillance for small renal masses in younger patients
Active surveillance (AS) is discussed as an option for renal masses <2cm in patients with significant competing risks for mortality. This multicentre data from the US seeks to fill an important gap in current guidelines for provision of this option...RSM: Urothelial cancer: advances, innovation and improving outcomes
Why attend? Hear from leading experts including Professor Param Mariappan, Professor Tom Powles, Professor Ben Challacombe and Professor Alison Birtle Explore how quality improvement initiatives, including lessons from Scotland's bladder cancer KPI programme, are shaping care delivery. Gain updates on...
